Results 31 to 40 of about 21,239 (239)

Identifcation of small molecule enzyme inhibitors as broad-spectrum anthelmintics [PDF]

, 2019
Targeting chokepoint enzymes in metabolic pathways has led to new drugs for cancers, autoimmune disorders and infectious diseases. This is also a cornerstone approach for discovery and development of anthelmintics against nematode and flatworm parasites.
Aroian, Raffi V., Brindley, Paul J., Bulman, Christina A., Elfawal, Mostafa A., Helander, Jon, Janetka, James W., Mitreva, Makedonka, Rosa, Bruce A., Sakanari, Judy, Tyagi, Rahul, Wildman, Scott A.   +10 more
core   +3 more sources

Role of ADMA/DDAH-1 and iNOS/eNOS signaling in the gastroprotective effect of tadalafil against indomethacin-induced gastric injury.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022
Non-steroidal anti-inflammatory drugs (NSAIDs)-induced gastric ulcers represent a significant clinical concern and adversely affect the quality of life.
Yasmin T. Mohamed, Ibrahim A. Naguib, Ali A Abo-Saif, Mohammed H. Elkomy, B. Alghamdi, W. Mohamed   +5 more
semanticscholar   +1 more source

A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis

BMC Urology, 2019
Background Chronic inflammation is thought to be a major causative factor for the development of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Tadalafil, a phosphodiesterase type 5 inhibitor (PDE5-I), which has been used for
Mikio Sugimoto, Xia Zhang, Nobufumi Ueda, Hiroyuki Tsunemori, Rikiya Taoka, Yusi Hayashida, Hiromi Hirama, Yasuyuki Miyauchi, Yuki Matsuoka, Hirohito Naito, Yu Osaki, Yosiyuki Kekehi   +11 more
doaj   +1 more source

Tadalafil monotherapy in management of chronic prostatitis/chronic pelvic pain syndrome: a randomized double-blind placebo controlled clinical trial

World journal of urology, 2022
In this placebo-controlled trial, we aimed to evaluate the clinical results of using PDE-5 inhibitor, tadalafil 5 mg OD, for management of CP/CPPS. 140 patients ≤ 45 years old with moderate/severe CP/CPPS associated with ED (IIEF-5 
A. Tawfik, M. Radwan, Mohammed Abdulmonem, Mohammed Abo-Elenen, S. Elgamal, Mohammed O. Aboufarha   +5 more
semanticscholar   +1 more source

An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy

Asian Journal of Andrology, 2015
The study was to compare treatment preference, efficacy, and tolerability of sildenafil citrate (sildenafil) and tadalafil for treating erectile dysfunction (ED) in Chinese men naοve to phosphodiesterase 5 (PDE5) inhibitor therapies.
Wen-Jun Bai, Hong-Jun Li, Yu-Tian Dai, Xue-You He, Yi-Ran Huang, Ji-Hong Liu, Sebastian Sorsaburu, Chen Ji, Jian-Jun Jin, Xiao-Feng Wang   +9 more
doaj   +1 more source

Redo pelvic fracture urethral injury repair: The case for tadalafil

Urology Research and Practice, 2021
Objective: To define the role of tadalafil in improving outcomes of redo urethroplasty for pelvic fracture urethral injury (PFUI). PFUI is common in developing countries, invariably as a result of road traffic trauma.
Devashree P. Joshi, Devang Desai, Seichi Fuziwara, Sheliyan Raveenthiran, Mohammed Nafea, Sanjay B. Kulkarni   +5 more
doaj   +1 more source

Phosphodiesterase Type 5 Inhibitors, Sport and Doping [PDF]

, 2017
Phosphodiesterase type 5 inhibitors (PDE5i) (e.g., sildenafil, tadalafil, vardenafil, and avanafil) are drugs commonly used to treat erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia.
Borrione, Paolo, CECI GALANOS, Roberta, Crescioli, Clara, Di Luigi, Luigi, Duranti, Guglielmo, Sabatini, Stefania, Sansone, Andrea, Sansone, Massimiliano, Sgrò, Paolo   +8 more
core   +1 more source

THE EFFECT OF COMBINED α1-ADRENERGIC BLOCKERS AND PDE-5 INHIBITORS THERAPY ON IPSS, IIEF-5, QMAX AND PVR PATIENTS BPH WITH LUTS AND ERECTILE DYSFUNCTION

Jurnal Urologi Indonesia, 2017
Purpose: Assess the efficacy of combined α1-adrenergic blocker (tamsulosin 0,4 mg) and PDE5 inhibitor (tadalafil 5 mg) therapy compared to tadalafil or tamsulosin alone in treating patient BPH with LUTS and ED.
Muhammad Ridha, Sunaryo Hardjowijoto, Johan Renaldo   +2 more
doaj   +1 more source

The phosphodiesterase 5 inhibitor sildenafil decreases the proinflammatory chemokine IL-8 in diabetic cardiomyopathy: in vivo and in vitro evidence [PDF]

, 2019
Purpose: Interleukin (IL)-8 is a proinflammatory C-X-C chemokine involved in inflammation underling cardiac diseases, primary or in comorbid condition, such diabetic cardiomyopathy (DCM).
Antinozzi, C., Basili, S., Colletti, M., Corinaldesi, C., Crescioli, C., Di Luigi, L., Filardi, T., Giannattasio, S., Lenzi, A., Morano, S., Scolletta, S.   +10 more
core   +1 more source

Meta-Analysis of the Long-Term Efficacy and Tolerance of Tadalafil Daily Compared With Tadalafil On-Demand in Treating Men With Erectile Dysfunction

Sexual Medicine, 2019
Background: Erectile dysfunction (ED) is highly prevalent in aging men. Tadalafil daily and on-demand are widely used for the treatment of ED. Aim: We performed a meta-analysis to evaluate the efficacy and safety of tadalafil daily compared with ...
Zhongbao Zhou, MM, Hongyan Chen, MM, Jitao Wu, MD, Jipeng Wang, MM, Xuebao Zhang, MM, Jiajia Ma, MM, Yuanshan Cui, MD   +6 more
doaj   +1 more source